Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
cancer
3
×
indiana blog main
indiana top stories
life sciences
national blog main
national top stories
san francisco blog main
3
×
san francisco top stories
biotech
blueprint medicines
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
europe blog main
europe top stories
fda
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
arena pharmaceuticals
avapritinib
boston
cancer drugs
capmatinib
cardiovascular disease
What
cancer
3
×
drug
fda
3
×
genetic
medicine
address
approval
approved
approves
blueprint
carries
certain
deeper
designed
dna
eisai
fingerprint
flags
going
higher
incidence
latest
lorcaserin
loss
market
marketing
matter
medicines
nd
new
oks
pass
patients
post
pulls
ret
risks
second
signature
signatures
Language
unset
Current search:
fda
×
cancer
×
" san francisco blog main "
×
cancer
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues